Short Interest in Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Drops By 21.0%

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCCGet Rating) was the target of a large drop in short interest in April. As of April 30th, there was short interest totalling 366,100 shares, a drop of 21.0% from the April 15th total of 463,600 shares. Currently, 4.5% of the company’s stock are short sold. Based on an average daily volume of 123,400 shares, the days-to-cover ratio is presently 3.0 days.

CYCC has been the subject of a number of analyst reports. Zacks Investment Research lowered shares of Cyclacel Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, April 21st. StockNews.com assumed coverage on shares of Cyclacel Pharmaceuticals in a research note on Friday. They issued a “sell” rating for the company.

Shares of CYCC stock opened at $1.39 on Monday. The company has a 50 day moving average price of $2.48 and a 200-day moving average price of $3.33. The firm has a market capitalization of $13.89 million, a PE ratio of -0.67 and a beta of 1.39. Cyclacel Pharmaceuticals has a 52 week low of $1.29 and a 52 week high of $7.95.

Cyclacel Pharmaceuticals (NASDAQ:CYCCGet Rating) last issued its quarterly earnings results on Monday, March 28th. The biotechnology company reported ($0.54) earnings per share for the quarter, beating the consensus estimate of ($0.71) by $0.17. During the same quarter in the previous year, the company posted ($1.34) EPS. Sell-side analysts forecast that Cyclacel Pharmaceuticals will post -2.37 EPS for the current year.

A number of large investors have recently modified their holdings of the business. Tri Locum Partners LP lifted its holdings in shares of Cyclacel Pharmaceuticals by 66.9% in the third quarter. Tri Locum Partners LP now owns 522,943 shares of the biotechnology company’s stock worth $2,756,000 after buying an additional 209,612 shares in the last quarter. Affinity Asset Advisors LLC lifted its holdings in shares of Cyclacel Pharmaceuticals by 5.3% in the third quarter. Affinity Asset Advisors LLC now owns 400,000 shares of the biotechnology company’s stock worth $2,108,000 after buying an additional 20,000 shares in the last quarter. Schonfeld Strategic Advisors LLC lifted its holdings in shares of Cyclacel Pharmaceuticals by 210.2% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 322,373 shares of the biotechnology company’s stock worth $1,254,000 after buying an additional 218,448 shares in the last quarter. Two Sigma Advisers LP lifted its holdings in shares of Cyclacel Pharmaceuticals by 929.7% in the third quarter. Two Sigma Advisers LP now owns 121,500 shares of the biotechnology company’s stock worth $640,000 after buying an additional 109,700 shares in the last quarter. Finally, Morgan Stanley lifted its holdings in shares of Cyclacel Pharmaceuticals by 21.3% in the second quarter. Morgan Stanley now owns 121,275 shares of the biotechnology company’s stock worth $718,000 after buying an additional 21,275 shares in the last quarter. 32.41% of the stock is currently owned by institutional investors and hedge funds.

Cyclacel Pharmaceuticals Company Profile (Get Rating)

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors.

Read More

Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.